ATE319458T1 - Medizinische zusammensetzungen zur behandlung von augenerkrankungen - Google Patents

Medizinische zusammensetzungen zur behandlung von augenerkrankungen

Info

Publication number
ATE319458T1
ATE319458T1 AT99940582T AT99940582T ATE319458T1 AT E319458 T1 ATE319458 T1 AT E319458T1 AT 99940582 T AT99940582 T AT 99940582T AT 99940582 T AT99940582 T AT 99940582T AT E319458 T1 ATE319458 T1 AT E319458T1
Authority
AT
Austria
Prior art keywords
eye diseases
treating eye
compositions
medical compositions
ocular tension
Prior art date
Application number
AT99940582T
Other languages
English (en)
Inventor
Kazuki Endo
Toichi Abiru
Tomokazu Hosokawa
Miwa Misawa
Takashi Konno
Original Assignee
Yamasa Corp
Toa Eiyo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamasa Corp, Toa Eiyo Ltd filed Critical Yamasa Corp
Application granted granted Critical
Publication of ATE319458T1 publication Critical patent/ATE319458T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99940582T 1998-09-01 1999-08-31 Medizinische zusammensetzungen zur behandlung von augenerkrankungen ATE319458T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24682698A JP2002173427A (ja) 1998-09-01 1998-09-01 眼疾患治療用医薬組成物

Publications (1)

Publication Number Publication Date
ATE319458T1 true ATE319458T1 (de) 2006-03-15

Family

ID=17154279

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940582T ATE319458T1 (de) 1998-09-01 1999-08-31 Medizinische zusammensetzungen zur behandlung von augenerkrankungen

Country Status (11)

Country Link
US (1) US6387889B1 (de)
EP (1) EP1110554B1 (de)
JP (1) JP2002173427A (de)
CN (1) CN1151794C (de)
AT (1) ATE319458T1 (de)
AU (1) AU5446299A (de)
CA (1) CA2342204A1 (de)
DE (1) DE69930271T8 (de)
DK (1) DK1110554T3 (de)
ES (1) ES2259842T3 (de)
WO (1) WO2000012098A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE263777T1 (de) * 1999-02-01 2004-04-15 Univ Virginia Zusammensetzungen zur behandlung von entzündungsreaktionen
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
ES2173027B2 (es) * 2000-07-06 2005-12-16 Universidad Complutense De Madrid Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular.
EP1316559B1 (de) * 2000-09-08 2004-11-03 Toa Eiyo Ltd. Adenosinderivate und deren verwendung
AU2001278708A1 (en) 2000-09-08 2002-03-22 Toa Eiyo Ltd. Adenosine derivatives and use thereof
SG176313A1 (en) * 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
EP1496911B1 (de) * 2002-04-10 2007-12-19 University Of Virginia Patent Foundation Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
EP1740587A4 (de) * 2004-04-02 2009-07-15 Adenosine Therapeutics Llc Selektive antagonisten von a2a-adenosinrezeptoren
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
CA2576826C (en) * 2004-08-02 2014-09-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
WO2008133129A1 (ja) * 2007-04-16 2008-11-06 Santen Pharmaceutical Co., Ltd. アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
EA201200635A1 (ru) * 2009-10-26 2012-10-30 Инотек Фармасьютикалз Корпорейшн Глазной состав и способ его изготовления
MX367879B (es) 2012-08-01 2019-09-10 Lewis And Clark Pharmaceuticals Inc N-alquil 2-(disustituido)alquiladenosin-5-uronamidas como agonistas a2a.
US9822141B2 (en) 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07106983B2 (ja) * 1987-12-02 1995-11-15 三共株式会社 グリゼオール酸ジエステル誘導体
DE68916036T2 (de) * 1988-11-15 1994-09-29 Toa Eiyo Ltd Mittel zur behandlung und prophylaxe koronarer und zerebraler ischämischer erkrankungen.
US5039797A (en) * 1989-10-13 1991-08-13 Yale University 2'-O-(4-benzoyl)benzoyl nucleoside cyclic monophosphate
FR2685918B1 (fr) * 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista

Also Published As

Publication number Publication date
CN1315862A (zh) 2001-10-03
EP1110554B1 (de) 2006-03-08
DE69930271T8 (de) 2006-12-28
AU5446299A (en) 2000-03-21
DE69930271D1 (de) 2006-05-04
DK1110554T3 (da) 2006-04-10
EP1110554A1 (de) 2001-06-27
CN1151794C (zh) 2004-06-02
CA2342204A1 (en) 2000-03-09
WO2000012098A1 (en) 2000-03-09
EP1110554A4 (de) 2002-02-06
US6387889B1 (en) 2002-05-14
JP2002173427A (ja) 2002-06-21
DE69930271T2 (de) 2006-08-24
ES2259842T3 (es) 2006-10-16

Similar Documents

Publication Publication Date Title
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
ES2062102T3 (es) Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular.
ATE426413T1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE286384T1 (de) Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
DK1239774T3 (da) Apparat til behandling af öjensygdomme
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
DE60106953D1 (de) Adenosinderivate und deren verwendung
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
ATE216889T1 (de) Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension
ATE204752T1 (de) Therapeutische anwendungen von 2',5'- oligoadenylat-derivaten
SE8901149D0 (sv) Medel foer inducering respektive foerhindrande av pupillkonstriktion i oegat
DE69713648D1 (de) Benzopyranderivate und ihre Verwendung zur Behandlung von Herzkrankheiten
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
DE69829227D1 (de) Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
BR0212274A (pt) Uso de estrogênios não-feminilizantes como agentes retinoprotetores para o tratamento de glaucoma
ATE186912T1 (de) Carbamoylpyrrolidon-derivate zur behandlung von depressionen und cerebrovasculären störungen
CA2219280A1 (en) Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties